Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 3
1978 1
1980 2
1982 1
1985 1
1987 1
1988 2
1991 1
1996 1
1998 1
2000 1
2001 5
2002 1
2011 1
2015 1
2017 1
2018 3
2019 2
2020 3
2021 3
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
The blood pressure control and arteriosclerotic cardiovascular risk among Chinese community hypertensive patients.
Liu S, Yuan H, Jiang C, Xu J, Qiu X, Luo J. Liu S, et al. Sci Rep. 2021 Sep 24;11(1):19066. doi: 10.1038/s41598-021-98745-8. Sci Rep. 2021. PMID: 34561523 Free PMC article.
The present study aimed to describe the blood pressure (BP) control rate and 10-years arteriosclerotic cardiovascular disease (ASCVD) risk estimation among community hypertensive patients. ...
The present study aimed to describe the blood pressure (BP) control rate and 10-years arteriosclerotic cardiovascular disea …
Endogenous Protective Factors and Potential Therapeutic Agents for Diabetes-Associated Atherosclerosis.
Wang C, Chen J, Wang P, Qing S, Li W, Lu J. Wang C, et al. Front Endocrinol (Lausanne). 2022 Apr 26;13:821028. doi: 10.3389/fendo.2022.821028. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35557850 Free PMC article. Review.
Among them, glucagon-like peptide-1 based drugs were clinically proven to be effective and recommended as the first-line medicine for the treatment of type 2 diabetic patients with high risks or established arteriosclerotic cardiovascular disease (CVD). Some …
Among them, glucagon-like peptide-1 based drugs were clinically proven to be effective and recommended as the first-line medicine for the tr …
Cardiovascular disease risk in liver transplant recipients transplanted due to chronic viral hepatitis.
Maggi P, Calò F, Messina V, Stornaiuolo G, Stanzione M, Rinaldi L, De Pascalis S, Macera M, Coppola N. Maggi P, et al. PLoS One. 2022 Mar 16;17(3):e0265178. doi: 10.1371/journal.pone.0265178. eCollection 2022. PLoS One. 2022. PMID: 35294954 Free PMC article.
RESULTS: A total of 161 patients were evaluated; of these 15 were excluded because not affected by viral hepatitis. 146 patients were considered. 83 patients (56.8%) were considered at high cardiovascular risk according to Framingham, 54 patients (36.9%) to American Heart Associa …
RESULTS: A total of 161 patients were evaluated; of these 15 were excluded because not affected by viral hepatitis. 146 patients were consid …
Prevalence rates of chronic kidney disease and its association with cardiometabolic factors and cardiovascular diseases. SIMETAP-CKD study.
Ruiz-Garcia A, Arranz-Martínez E, Iturmendi-Martínez N, Fernández-Vicente T, Rivera-Teijido M, García-Álvarez JC. Ruiz-Garcia A, et al. Clin Investig Arterioscler. 2023 Mar-Apr;35(2):64-74. doi: 10.1016/j.arteri.2022.07.002. Epub 2022 Aug 6. Clin Investig Arterioscler. 2023. PMID: 35945036 English, Spanish.
INTRODUCTION: Chronic kidney disease (CKD) is a major health problem that contributes to the development of cardiovascular disorders such as heart failure and arteriosclerotic cardiovascular disease (ACVD). The aims of this study were to determine the prevale …
INTRODUCTION: Chronic kidney disease (CKD) is a major health problem that contributes to the development of cardiovascular disorders such as …
JCL Roundtable: is inflammation a future target in preventing arteriosclerotic cardiovascular disease.
Brown WV, Remaley AT, Ridker PM. Brown WV, et al. J Clin Lipidol. 2015 Mar-Apr;9(2):119-28. doi: 10.1016/j.jacl.2015.01.007. Epub 2015 Jan 30. J Clin Lipidol. 2015. PMID: 25911071 Review.
Much research has provided evidence as to how the invading cells interact with the basic components of the arterial structure to produce the damage observed throughout the vessel wall. We have focused our preventive efforts on the clinical risk factors with significant but …
Much research has provided evidence as to how the invading cells interact with the basic components of the arterial structure to produce the …
The effects of statins on dental and oral health: a review of preclinical and clinical studies.
Tahamtan S, Shirban F, Bagherniya M, Johnston TP, Sahebkar A. Tahamtan S, et al. J Transl Med. 2020 Apr 6;18(1):155. doi: 10.1186/s12967-020-02326-8. J Transl Med. 2020. PMID: 32252793 Free PMC article. Review.
The statin family of drugs are safe and effective therapeutic agents for the treatment of arteriosclerotic cardiovascular disease (CVD). Due to a wide range of health benefits in addition to their cholesterol lowering properties, statins have recently attract …
The statin family of drugs are safe and effective therapeutic agents for the treatment of arteriosclerotic cardiovascular d …
Quality of Cardiovascular Disease Care in Small Urban Practices.
Shelley D, Blechter B, Siman N, Jiang N, Cleland C, Ogedegbe G, Williams S, Wu W, Rogers E, Berry C. Shelley D, et al. Ann Fam Med. 2018 Apr;16(Suppl 1):S21-S28. doi: 10.1370/afm.2174. Ann Fam Med. 2018. PMID: 29632222 Free PMC article. Clinical Trial.
PURPOSE: We wanted to describe small, independent primary care practices' performance in meeting the Million Hearts ABCSs (aspirin use, blood pressure control, cholesterol management, and smoking screening and counseling), as well as on a composite measure that captured the exten …
PURPOSE: We wanted to describe small, independent primary care practices' performance in meeting the Million Hearts ABCSs (aspirin use, bloo …
Treatment of hyperhomocysteinemia in end-stage renal disease.
Shemin D, Bostom AG, Selhub J. Shemin D, et al. Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S91-4. doi: 10.1053/ajkd.2001.27412. Am J Kidney Dis. 2001. PMID: 11576930 Review.
The reported association between Hhcy and the development of arteriosclerotic cardiovascular disease may account, in part, for the disproportionate risk for cardiovascular morbidity and mortality in patients with chronic renal disease. ...Data from this tr …
The reported association between Hhcy and the development of arteriosclerotic cardiovascular disease may account, in pa …
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M. Bostom AG, et al. Circulation. 2011 Apr 26;123(16):1763-70. doi: 10.1161/CIRCULATIONAHA.110.000588. Epub 2011 Apr 11. Circulation. 2011. PMID: 21482964 Free PMC article. Clinical Trial.
The impact of lowering total homocysteine levels in kidney transplant recipients is unknown. METHODS AND RESULTS: In a double-blind controlled trial, we randomized 4110 stable kidney transplant recipients to a multivitamin that included either a high dose (n=2056) o …
The impact of lowering total homocysteine levels in kidney transplant recipients is unknown. METHODS AND RESULTS: In a double-blind controll …
Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
Masana L, López Miranda J, Civeira F, Reinares L, Guijarro C, Plana N, Cuenca R, Sánchez D, Hernández JL, Andrés R, Blanco A, Villamayor S. Masana L, et al. Clin Investig Arterioscler. 2020 Sep-Oct;32(5):183-192. doi: 10.1016/j.arteri.2020.02.003. Epub 2020 Apr 18. Clin Investig Arterioscler. 2020. PMID: 32317124 Free article. English, Spanish.
OBJECTIVE: To describe the clinical characteristics, the reasons for initiating therapy, and the effects of treatment in the initial phase of evolocumab availability in lipid/internal medicine units in Spain. ...The initial use of evolocumab was in accordance with the guid …
OBJECTIVE: To describe the clinical characteristics, the reasons for initiating therapy, and the effects of treatment in the initial …
39 results